- Home
- TFIN vs WVE Comparison
TFIN vs WVE Comparison
Compare TFIN & WVE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TFIN
- WVE
- Stock Information
- Founded
- TFIN 1981
- WVE 2012
- Country
- TFIN United States
- WVE Singapore
- Employees
- TFIN N/A
- WVE N/A
- Industry
- TFIN Major Banks
- WVE Biotechnology: Pharmaceutical Preparations
- Sector
- TFIN Finance
- WVE Health Care
- Exchange
- TFIN Nasdaq
- WVE Nasdaq
- Market Cap
- TFIN 2.0B
- WVE 2.4B
- IPO Year
- TFIN N/A
- WVE 2015
- Fundamental
- Price
- TFIN $98.29
- WVE $13.67
- Analyst Decision
- TFIN Hold
- WVE Strong Buy
- Analyst Count
- TFIN 5
- WVE 10
- Target Price
- TFIN $71.80
- WVE $21.30
- AVG Volume (30 Days)
- TFIN 146.3K
- WVE 1.3M
- Earning Date
- TFIN 10-16-2024
- WVE 11-12-2024
- Dividend Yield
- TFIN N/A
- WVE N/A
- EPS Growth
- TFIN N/A
- WVE N/A
- EPS
- TFIN 0.80
- WVE N/A
- Revenue
- TFIN $398,012,000.00
- WVE $53,610,000.00
- Revenue This Year
- TFIN N/A
- WVE N/A
- Revenue Next Year
- TFIN $10.19
- WVE N/A
- P/E Ratio
- TFIN $126.03
- WVE N/A
- Revenue Growth
- TFIN N/A
- WVE N/A
- 52 Week Low
- TFIN $66.61
- WVE $3.50
- 52 Week High
- TFIN $105.05
- WVE $16.74
- Technical
- Relative Strength Index (RSI)
- TFIN 62.04
- WVE 50.96
- Support Level
- TFIN $85.88
- WVE $14.95
- Resistance Level
- TFIN $105.05
- WVE $16.71
- Average True Range (ATR)
- TFIN 3.28
- WVE 1.04
- MACD
- TFIN 0.62
- WVE -0.28
- Stochastic Oscillator
- TFIN 64.75
- WVE 14.72
About TFIN Triumph Financial Inc.
Triumph Financial Inc is a is a financial holding company. The company has four reportable segments namely Banking, Factoring, Payments, and Corporate. The Banking segment includes the operations of TBK Bank. The Factoring segment includes the operations of Triumph Financial Services with revenue derived from factoring services, The Payments segment includes the operations of TBK Bank's TriumphPay division which provides a presentment, audit and payment solution to Shipper, Broker, and Factor clients in the trucking industry and The corporate segment includes holding company financing and investment activities and management and administrative expenses to support the overall operations of the Company.
About WVE Wave Life Sciences Ltd.
WAVE Life Sciences Ltd is unlocking the broad potential of RNA medicines also known as oligonucleotides, it targeting ribonucleic acid (RNA), to transform human health. RNA medicines platform, PRISMTM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, splicing, antisense silencing, and RNA interference, providing capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its programs are for rare and prevalent diseases, including alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington's disease.